LY-2183240 is a covalent inhibitor of fatty acid amide hydrolase (FAAH), an enzyme responsible for the degradation of endocannabinoids (ECs). It disrupts cellular uptake of lipid endocannabinoids and promotes analgesic effects in vivo. Additionally, LY-2183240 acts as an inhibitor of monoacylglycerol lipase (MGL). In animal studies, it dose-dependently attenuates formalin-induced paw-licking pain behavior in the formalin model of persistent pain in male Sprague-Dawley rats when administered intraperitoneally at doses of 3–30 mg/kg.